Standout Papers
Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules
2011
Anticoagulant Use in Patients with Chronic Renal Impairment
2005
Coadministration of Dabigatran Etexilate and Atorvastatin
2009
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment
2008
Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)
2003
Nonadherence in outpatient thromboprophylaxis after major orthopedic surgery: a systematic review
2010
Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis
2002
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis
2013
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
2010
Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study
2005
Interventions for preventing venous thromboembolism in adults undergoing knee athroscopy
2007
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN)
2012
Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open‐label study
2006
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
2010
Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery
2003
New oral antithrombotics: a need for laboratory monitoring. For
2010
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
2010
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
2010 StandoutNobel
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
2010 Standout
Arthroscopic surgery for degenerative knee: systematic review and meta-analysis of benefits and harms
2015
Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate
2008
The Use of Dabigatran Immediately After Atrial Fibrillation Ablation
2011
Drug-Induced Liver Injury in Humans: The Case of Ximelagatran
2009
Perioperative Management of Antithrombotic Therapy
2012 Standout
Oral Anticoagulant Therapy
2012 Standout
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
2008
Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology
2014
Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran
2008
New Antithrombotic Drugs
2012
The Cost-Effectiveness of Extended-Duration Antithrombotic Prophylaxis After Total Hip Arthroplasty
2007
Antithrombotic Therapy for VTE Disease
2016 Standout
Venous Thromboembolism Is Rare with a Multimodal Prophylaxis Protocol after Total Hip Arthroplasty
2006
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation
2006
The procoagulant potential of environmental particles (PM10)
2005
Extended duration of thromboprophylaxis in acutely ill medical patients: optimizing therapy?
2006
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
2008
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
2009
Rivaroxaban
2011
Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
2008
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
2010
Duration of Prophylaxis Against Venous Thromboembolism With Fondaparinux After Hip Fracture Surgery<subtitle>A Multicenter, Randomized, Placebo-Controlled, Double-blind Study</subtitle>
2003
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty
2010
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
2005
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
2013
Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double‐blind comparison
2007
New Antithrombotic Drugs
2009
Severe Sepsis and Septic Shock
2013 Standout
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients
2000
Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement
2003
Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients
2003
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
2009
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Low-Molecular-Weight Heparin Prophylaxis of Deep Vein Thrombosis for Older Patients with Restricted Mobility
2009
Prevention of fatal pulmonary embolism and mortality in surgical patients
2005
The Benefit of Aspirin Chemoprophylaxis for Thromboembolism after Total Knee Arthroplasty
2006
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
2010 Standout
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
2005
Adverse Outcomes Associated With Elective Knee Arthroscopy: A Population-Based Cohort Study
2013
Risk Factors for Venous Thromboembolism in Patients Undergoing Total Hip Replacement and Receiving Routine Thromboprophylaxis
2010
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Characterization of Post-Operative Risk Associated With Prior Drug-Eluting Stent Use
2009
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery
2007
A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study
2010
Antiplatelet Drugs
2012
Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART Study
2004
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis
2007
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
2005
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
2010
Perioperative venous thromboembolism prophylaxis in Israel: a survey of academic surgical departments
2004
Executive Summary
2012 Standout
Approach to Outcome Measurement in the Prevention of Thrombosis in Surgical and Medical Patients
2012
Stroke
2008 Standout
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement
2010
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
2007
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects
2009
Heparin-Induced Thrombocytopenia
2006 Standout
Prevention of venous thromboembolism in spinal surgery
2003
Prevention of VTE in Nonorthopedic Surgical Patients
2012 Standout
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Ultrasound screening for distal vein thrombosis is not beneficial after major orthopedic surgery.
2003
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation
2005
Preoperative or Postoperative Start of Prophylaxis for Venous Thromboembolism With Low-Molecular-Weight Heparin in Elective Hip Surgery?
2002
Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
2009
The 2007 ABJS Nicolas Andry Award: Three Decades of Clinical, Basic, and Applied Research on Thromboembolic Disease after THA
2007
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
2010
Venous thromboembolism (VTE) in Europe
2007 Standout
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
2002 Standout
Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications
2008
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study
2003
Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome
2011
Medical literature, vena cava filters and evidence of efficacy
2013
New Anticoagulant Agents: Direct Thrombin Inhibitors
2008
Flexibility in Administration of Fondaparinux for Prevention of Symptomatic Venous Thromboembolism in Orthopaedic Surgery
2006
Prevention of Venous Thromboembolism
2004 Standout
Antithrombotic Therapy in Atrial Fibrillation
2004
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin
2006
Ulcerative colitis
2016 Standout
Neuraxial Anesthesia and Low-Molecular-Weight Heparin Prophylaxis in Major Orthopedic Surgery in the Wake of the Latest American Society of Regional Anesthesia Guidelines
2005
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism
2005
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial
2003
Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors
2005
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1
2007
Thrombotic complications in beating heart operations
2001
Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis
2005
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement
2005
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
2007 Standout
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score
2010
Idarucizumab for Dabigatran Reversal
2015 Standout
Prevention of Venous Thromboembolism
2008 Standout
Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification
2010
Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility
2010
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
2007
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
2003
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
2010 Standout
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study
2003
Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity
2006
Relationship Between Deep Venous Thrombosis and the Postthrombotic Syndrome
2004
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study
2007
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
2012
The post-thrombotic syndrome: current knowledge, controversies, and directions for future research
2002
Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation
2011
Venous Thromboembolism in Patients Undergoing Laparoscopic and Arthroscopic Surgery and in Leg Casts
2002
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
2009
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery
2004
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
2009
Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases
2008
Prolonged thromboprophylaxis with low molecular weight heparin after major abdominal surgery
2007
Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation
2012
Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery
2003
Deep vein thrombosis
2005
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2007 Standout
Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery
2007
A dose‐ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty
2010
Osteoarthritis
2019 Standout
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement
2003
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)
2011
Thromboembolic Risk Assessment and the Efficacy of Enoxaparin Prophylaxis in Excisional Body Contouring Surgery
2008
Thromboprophylaxis Is Associated With Reduced Post-hospitalization Venous Thromboembolic Events in Patients With Inflammatory Bowel Diseases
2014
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
2010 StandoutNobel
Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta‐analysis
2004
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review
2004
Clinical performance of bleeding risk scores for predicting major and clinically relevant non‐major bleeding events in patients receiving warfarin
2013
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban
2010
INCIDENCE RATES OF DISLOCATION, PULMONARY EMBOLISM, AND DEEP INFECTION DURING THE FIRST SIX MONTHS AFTER ELECTIVE TOTAL HIP REPLACEMENT
2003
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines
2012
Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects
2007
Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
2006
Tranexamic Acid Reduces Blood Loss in Total Hip Replacement Surgery
2000
Antithrombotic Therapy in Atrial Fibrillation
2008
Dabigatran Association With Higher Risk of Acute Coronary Events
2012
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty
2010
Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin
2003
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy
2008
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
The Cost-Effectiveness of Extended-Duration Antithrombotic Prophylaxis After Total Hip Arthroplasty
2007
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
2004
Frequency and timing of clinical venous thromboembolism after major joint surgery
2006
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
2017 Standout
Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery
2004
Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review.
2003
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
2008
Ximelagatran and melagatran vs. low‐molecular‐weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration
2005
Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients
2003
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies
2014
New concepts in orthopaedic thromboprophylaxis
2004
Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
1997
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
2003
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study
2008
Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization
2017
Lessons From Ximelagatran: Issues for Future Studies Evaluating New Oral Direct Thrombin Inhibitors for Venous Thromboembolism Prophylaxis in Orthopedic Surgery
2008
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism
2012
Economic and Practical Aspects of Thromboprophylaxis With Unfractionated and Low-Molecular-Weight Heparins in Hospitalized Medical Patients
2009
A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
2000
ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY
2005
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation
2007
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials
2009
Low risk of thromboembolic complications after fast-track hip and knee arthroplasty
2010
Dabigatran Versus Warfarin in Patients With Atrial Fibrillation
2011
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement
2009
Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery
2005
Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
2005
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2010
Prolonged thromboprophylaxis with Low Molecular Weight heparin for abdominal or pelvic surgery
2009
Superficial Venous Thrombosis and Venous Thromboembolism
2010
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Tranexamic Acid Reduces Blood Loss in Total Hip Replacement Surgery
2000
Particulate Matter Air Pollution and Cardiovascular Disease
2010 Standout
Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
2008
Managing anticoagulant and antiplatelet drugs in patients who are receiving neuraxial anesthesia and epidural analgesia: a practical guide for clinicians
2006
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Development and validation of a predictive model for chemotherapy-associated thrombosis
2008 Standout
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)
2007
Recent Advances in Venous Thromboembolic Prophylaxis During and After Total Hip Replacement
2000
Natural History of Venous Thromboembolism
2004
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial
2007
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 Standout
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Prevention of deep vein thrombosis and pulmonary embolism
2015
Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
2005
Rivaroxaban: A New Oral Factor Xa Inhibitor
2010
Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial.
2008
Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use.
2008
Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery
2005
Works of Ola E. Dahl being referenced
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies
2007
Late occurring clinical deep vein thrombosis in joint-operated patients
2000
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
2008
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial
2002
Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery
1995
Prevention of VTE in Orthopedic Surgery Patients
2012 Standout
SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery
2008
Orthopaedic Surgery as a Model for Drug Development in Thrombosis
2004
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
2008
Studies on coagulation, fibrinolysis, kallikrein-kinin and complement activation in systemic and pulmonary circulation during hip arthroplasty with acrylic cement
1988
Fatal vascular outcomes following major orthopedic surgery
2005
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
2007
Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
2005
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
2007
The role of the pulmonary circulation in the regulation of coagulation and fibrinolysis in relation to major surgery
1997
Thromboprophylaxis in hip arthroplasty: New frontiers and future strategy
1998
Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery
1993
Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery
2002
THE EXPRESS STUDY: PRELIMINARY RESULTS
2003
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty
2001
Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.
2006
Dabigatran Etexilate for the Prophylaxis of Venous Thromboembolism After Hip or Knee Replacement Rationale for Dose Regimen
2009
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
2008
An electronic tool for venous thromboembolism prevention in medical and surgical patients.
2006
Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.
2005
Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital
2003
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
2006
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement
2003
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review.
2001
Mechanisms of Hypercoagulability
1999
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.
2003
Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.
2007